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Abstract
The 100,000 Genomes Project is a hybrid clinical and research project in which patients and parents are offered genome
sequencing for cancer and rare and inherited disease diagnosis; all participants receive their main findings and contribute
their data for research, and are offered optional secondary findings. Our aim was to explore participating parents’ attitudes
towards and understanding of genome sequencing in this hybrid context. We conducted in-depth telephone interviews with
20 parents of children with rare diseases participating in the 100,000 Genomes Project. Parents were positive about
contributing to research, although some had needed reassurance about data protections. Although most felt positive about
secondary findings, some could not recall or misunderstood key aspects. Some were also concerned about potential
emotional impact of results and a few raised concerns about life insurance implications, and the impact of future legal
changes. Participants were generally positive about consent appointments, but several raised concerns about ‘information
overload’ because of deciding about secondary findings at the same time as about the main diagnostic genome sequencing
and data contribution. Additional information resources, particularly online tools, were highlighted as potentially useful
ways of supporting the consent process. We conclude that parents offered genome sequencing as part of a national hybrid
clinical and research project report many positive attitudes and experiences, but also concerns and misunderstandings.
Further research is needed on how best to support informed consent, particularly about secondary findings. Additional
resources such as online tools might usefully support future genome sequencing consent processes.
Introduction
Next-generation sequencing technologies including genome
sequencing are increasingly being utilised to aid the diag-
nosis of children and adults with rare and inherited diseases
[1, 2]. The search for a genetic diagnosis can be a long and
arduous journey, and patients are likely to have undergone
extensive medical testing during this time [3]. Genome
sequencing has the potential to reduce this ‘diagnostic
odyssey’ for many patients and their families. The benefits
of obtaining a genetic diagnosis include the potential for
more accurate treatments, a clearer prognosis, information
about recurrence risk and opportunities to make contact
with other families with the same diagnosis through support
groups [4, 5]. The diagnostic yield of genome sequencing
for previously unsolved paediatric cases is up to around
40% (depending on the clinical indication), and this is
likely to continue to increase as knowledge grows [1].
In addition to the benefits of genome sequencing, there are
also potential challenges including: identifying patients’
These authors contributed equally: Celine Lewis, Saskia Sanderson
* Celine Lewis
celine.lewis@ucl.ac.uk
1 London North Genomic Laboratory Hub, Great Ormond Street
Hospital for Children NHS Foundation Trust, London, UK
2 UCL Great Ormond Street Institute of Child Health, London, UK
3 Institute of Health Informatics, University College London,
London, UK
4 Genomics England, Queen Mary University of London, Dawson
Hall, London, UK
5 Faculty of Health and Wellbeing, Sheffield Hallam University,
Sheffield, UK
6 Society and Ethics Research, Wellcome Genome Campus,
Cambridge, UK
7 Unique—Rare Chromosome Disorder Support Group, Oxted, UK
8 Genetic Alliance UK, London, UK
Supplementary information The online version of this article (https://
doi.org/10.1038/s41431-020-0575-2) contains supplementary
material, which is available to authorized users.
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
information needs, facilitating decisions about testing and
research participation, managing varying levels of genomic
literacy, managing patients’ expectations and determining
whether and how secondary findings should be offered to
patients [6, 7].
The 100,000 Genomes Project was set up in England in
2015 to pilot the introduction of genome sequencing as part
of a new NHS Genomic Medicine Service. The 100,000
Genomes Project is a hybrid clinical practice and research
project, with four overarching aims: “to bring benefit to
patients and set up a genomic medicine service for the NHS;
to create an ethical and transparent programme based on
consent; to enable new scientific discovery and medical
insights; and to kick-start the development of a UK genomics
industry” [8, 9]. Tens of thousands of patients with cancer, or
with selected rare and inherited diseases, and parents of the
patients with rare diseases, were enrolled between 2015 and
2018. Receiving main findings relating to the proband’s
condition, and having sequencing data and medical records
stored in a biorepository for research purposes, were condi-
tions of participation. Participants could also choose whether
they wanted to receive clinically actionable ‘secondary
findings’ (or ‘additional findings’) in their DNA sequence
data. The genes/conditions currently on this secondary find-
ings list (although subject to change) include hereditary
breast and ovarian cancer (BRCA1/2), hereditary colorectal
cancer (Lynch syndrome) and familial hypercholester-
olaemia, as well as parental carrier status for cystic fibrosis
[10]. These are not labelled ‘incidental findings’ because they
are actively searched for rather than arising unexpectedly. At
the time of writing (15th August 2019), no secondary findings
had yet been returned to participants.
The subject of secondary findings raises a number of
ethical and clinical issues. Whilst studies have shown that
most key stakeholders think that both actionable and non-
actionable secondary findings should be returned [11, 12],
healthcare professionals have acknowledged the increase in
workload of clinical scientists and clinicians in interpreting
and returning such results [12]. Questions have also been
raised about who should consent patients and deliver test
results [13]. The potential to cause anxiety or psychological
harm to patients associated with ‘the burden of knowing’, as
well as concerns around discrimination in insurance and
employment, have also been identified [12].
As genome sequencing is now being implemented in
healthcare systems globally, including in the new NHS
Genomic Medicine Service in England, it is important that
patients’ views and experiences of genome sequencing are
understood. In-depth qualitative research can provide
insights on patients’ views and experiences that may be
valuable to policy makers, healthcare professionals and
researchers involved in developing resources, information
materials and protocols for future genomic medicine
projects and services. For example, interviews with patients
can highlight topics covered during the consent process that
were less well understood, identify patients’ information
needs and uncover patients’ concerns that need addressing.
In addition, emergent themes from this type of in-depth
qualitative research can be used to generate testable
hypotheses and develop new measures for use in large-scale
quantitative survey studies [14].
A few recent qualitative interview studies have started to
shed light on the perspectives of parents who have been
offered genomic (exome or genome) sequencing to diagnose
their child’s rare conditions in the UK [15], US [16, 17],
Canada [18] and the Netherlands [19]. These studies have
highlighted common motivational factors for consenting to
genomic testing such as desire for a diagnosis and con-
tributing to science [16], but have also identified concerns
around elevated expectations and loss of hope for recovery
following a diagnosis [17]. The 100,000 Genomes Project
now provides a valuable opportunity to learn how patients
and their relatives respond when offered genome sequencing
within the UK NHS, in a hybrid clinical and research con-
text, including mandatory contribution of personal health
data for research, and optional secondary findings. One
previous qualitative interview study with 20 participants in
the 100,000 Genomes Project was recently published [20].
That study highlighted participants’ attitudes specifically
regarding trust in the NHS and views towards data access by
commercial companies. However, participants’ broader
attitudes towards, and understanding of, the diagnostic and
secondary findings offered were not explored.
Our overarching objectives in this study were therefore
to explore the themes that arise when participants talk about
their understanding, attitudes and experiences regarding the
clinical diagnostic aspects, contributing personal health data
for research purposes and secondary findings when under-
going genome sequencing in this clinical and research
context. Our primary aim was to identify themes that would
be useful for policy and practice, particularly for the new
NHS Genomic Medicine Service and other similar health-
care systems now being implemented. Our secondary aim
was to use emergent themes to develop new quantitative
survey measures for use in ongoing and future large-scale
genomics research on patient-reported outcomes and
experiences.
Methods
Study design and setting
This was a qualitative interview study conducted after
parents had consented to genome sequencing, but before
they had received any main or secondary findings from the
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project. Approval was obtained from the NHS Research
Ethics Committee West Midlands (15/WM/0258). Recruit-
ment was conducted in a London children’s hospital
in a Genomic Medicine Centre between June 2016 and
March 2017.
Participants and recruitment
Participants were eligible if they were: parents of children
with rare diseases who had consented to genome sequen-
cing in the 100,000 Genomes Project and had blood taken;
were able to read the information materials and could
complete the interview in English. To recruit participants
for the interviews, healthcare professionals who were con-
senting families to the 100,000 Genomes Project invited a
continuous sample of potential participants at the end of the
consent appointment. After being given a short description
of the study, parents who were interested were asked to
complete a ‘consent to contact’ form with their name and
contact details. One of two researchers (SS, CL) then con-
tacted interested parents to discuss the study further with
them; interested parents were then sent a participant infor-
mation sheet via email or post. A telephone interview was
then arranged with those willing to take part. Parents of
children with rare diseases often have multiple caring
commitments and children with complex needs, and many
of the families attending the recruiting hospital live far
away. We therefore opted for telephone interviews rather
than face-to-face to make it more convenient for the parents.
In total, 57 parents were initially approached to take part
in this study and signed a ‘consent to contact’ form.
Attempts were made to contact the first 40 of these parents.
Of these 40, 14 were ‘passive decliners’ (six did not answer
the phone calls and eight did not reply to emails) and six
were ‘active decliners’ (five agreed to participate but sub-
sequently did not answer when called for a scheduled
interview, and one actively declined to participate when
invited). Data saturation was reached after 20 interviews.
The remaining 17 parents who had initially been approa-
ched were therefore not contacted. The 20 interviews were
conducted between 5 days and 17 weeks following
recruitment into the 100,000 Genomes Project (median
7 weeks). The mean interview length was 28 min, and
interviews ranged from 11 to 53 min. The 11-min interview
was an outlier and was particularly brief because the par-
ticipant gave only very short answers to all questions
despite the open-ended questions and probes. Sixteen of the
interviews were conducted by SS and four by CL.
Topic guide
An interview topic guide (Supplementary File) informed by
the literature [21] and the advisory team (comprising three
genetic health professionals, two social/behavioural scien-
tists, two patient advocates from support groups and a lay
member who was a participant in the 100,000 Genomes
Project), was developed by SS and CL with questions being
refined after the first few interviews had taken place. Topics
included: understanding (the purpose of genome sequen-
cing, whether they will get a result, how their genomic data
will be used, who will have access to it etc); motivations
and concerns around main findings and secondary findings
including whether they consented to secondary findings;
information needs and satisfaction with the consent proce-
dures and materials.
Data analysis
Audio recordings were transcribed verbatim and de-
identified. Thematic analysis was used to analyse the tran-
scripts, which involved an iterative process where data were
coded, compared, contrasted and refined to generate emer-
gent themes [22]. The themes were organised to map on to
the overarching aims, that is, exploring understanding and
attitudes towards diagnosis, research uses of data and sec-
ondary findings. To develop the code book, two investiga-
tors experienced in qualitative analysis (SS and CL) each
read three transcripts and went through an iterative process
of revising and refining the code book. First, SS and CL
independently developed an initial draught codebook
informed by the aims of the study and by reading and
reviewing the same transcript; these were compared and
combined into a single codebook after discussion. Next, the
two investigators independently coded a second transcript;
disagreements were resolved, and minor codebook revisions
were made. Each investigator then independently coded a
third transcript. The Kappa for the two sets of codes indi-
cated good inter-rater agreement. Both investigators then
independently coded the remaining transcripts using the
final code book (SS coded nine and CL coded eight). Once
all transcripts were coded, both investigators reviewed and
revised the codes together. NVivo 10 (QSR International,
Australia) was used to manage the data and facilitate cod-
ing. Names used in quotes are not individuals’ real names.
Results
Participants
The 20 participants were parents (13 mothers, 7 fathers) of
21 children affected by a range of rare conditions (Table 1),
of whom eight had no diagnosis and 13 had a general
‘working diagnosis’ (i.e. a broad label used to describe the
condition e.g. intellectual disability, autism or epilepsy)
with an unknown genetic aetiology.
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Attitudes towards the clinical purpose of the
sequencing
Understanding
Participants understood that a major reason for their being
invited in to the 100,000 Genomes Project was to obtain a
diagnosis for their child, and several evidenced under-
standing that this could have potential implications for
family members. Around half explicitly stated that they
might not get a diagnosis. See Table 2 for illustrative
quotes.
Perceived benefits
All participants stated that their desire for a diagnosis was
an important reason for their agreeing to genome sequen-
cing. They wanted a “definite answer”, to “get to the root
of the problem” or, where there was already a diagnosis
based on clinical features, to obtain a better understanding
of the underlying genetic cause of their child’s rare condi-
tion. Several referred to genome sequencing as being the
last opportunity to get a diagnosis, e.g. it was something
“we’ve got to do”. Some talked about wanting a diagnosis
in order to have a clearer prognosis for their child, e.g. “to
know what his future holds”. A few talked about the need to
understand why their child had died and the emotional
Table 1 Participant characteristics.
Characteristic N or range and mean
Age of participant 25–49 years; mean= 39 years
Sex of participant
Female 13
Male 7
Age of child 10 months–18 years; mean=
10 years; 2 children were
deceased
Gender of child
Female 8
Male 13
Condition type
Neurological 6
Intellectual disability/
developmental delay
5
Metabolic 3
Mitochondrial 2
Endocrine 2
Cardiovascular 1
Dermatological 1
Primary ciliary disorder 1
Diagnosis with unknown genetic aetiology
‘Working diagnosis’ 13
None 8
One parent had two children enrolled in the study.
Table 2 Understanding and attitudes towards the clinical purpose of the sequencing.
Categories Themes Example quotes
Understanding To obtain a diagnosis “This is where they can do testing for him to try and find his diagnosis” P07
Implications for family members “Sarah has got two brothers…if they’re carriers of the gene then they may pass that
on” P02
Might not get a diagnosis “we’re very realistic about the potential for it to come back with nothing” P01
Perceived benefits Desire for diagnosis “when you spend so much time trying to find a diagnosis, you’re not going to say
no” P18
Last opportunity for diagnosis “If this can’t yield [a diagnosis], I don’t know else would to be quite honest with
you” P06
Desire for clearer prognosis “for information potentially about life expectancy” P04
Need to understand why “That need to know never leaves you… you always wonder why, how, was it you,
was there something you could do?” P16
Possibility of better treatments “develop a drug that’s not an injection” P15
Family planning “If [my daughter] is going to have children, is it going to be passed on?” P16
Curiosity about the rare condition “wouldn’t impact treatment because they already know what’s going on” P15
Concerns Prognosis more serious than initially
anticipated
“if it’s one of the syndromes then there’s a possibility he could go blind” P02
Anxious might have passed
condition on
“it’s also hard because if something comes back in my DNA that says that I cause
my son to be the way he is…that’s going to be really hard to accept” P07
Not wanting to get your hopes up “”I don’t want to get my hopes up that there is a definite diagnosis that we’re going
to receive” P16
Blood test “[my child] doesn’t like blood tests” P08
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impact of not knowing (“having all of that weight on your
own shoulders”). A number of participants discussed the
possibility of improved or more accurate treatments for their
child, e.g. “develop new medication.” Only a couple of
participants mentioned “possibly finding a cure” for their
child. Several parents talked about being generally curious
about the rare condition rather than anticipating specific
benefits. The other key benefit was around family planning,
either for themselves or their children.
Concerns
A number of participants expressed concerns about the
potential emotional impact of receiving, or not receiving, a
diagnostic result from the genome sequencing. For exam-
ple, a few were anxious that the diagnosis might show the
prognosis to be more serious than anticipated, with one
commenting that a diagnosis of one particular condition
would confirm the possibility that their child could go blind.
Within this theme, some expressed concerns about how
they might feel if they found out they had passed on the
condition to their child, for example, “that’s going to be
really hard to accept”, and a few spoke of not wanting to
get their “hopes up” in case they did not get an informative
result. The only practical concern cited was the child’s
dislike of blood tests.
Attitudes towards the research uses of their data
Understanding
Participants appeared to understand that, in addition to
the clinical diagnostic purpose, a major goal of the
100,000 Genomes Project was to contribute to research
(“wider research” and “advance medicine”). In terms of
demonstrating understanding of who would have access to
their data, there was evidence in several interviews that
participants understood commercial organisations would
be allowed to access their child’s genomic data, but only
one participant explicitly stated university researchers
could also potentially access the data. In terms of
demonstrating understanding how their data would be
protected (data protection), several reflected under-
standing that the “information is anonymised” and “the
database will only hold ID numbers and no names”.
Several also displayed understanding about how the data
would be stored (data storage), e.g. that it would be held
in a “national database”. However, one mistakenly
thought the database would be kept within their specific
healthcare institution. None of the participants specifically
exhibited the understanding that, because rare diseases
can affect extremely small numbers in the UK, there was a
small risk that they or their child might be identified as
someone taking part in the project.
Perceived benefits
When asked about their motivations for genome sequencing,
around half the participants said that they were motivated by a
desire to help others with the same condition via the research
aspect of the 100,00 Genomes Project. Several said they had
no concerns even if their genomic data were to be made
publically available, if it could potentially lead to beneficial
research. Within this theme, a sub-theme was that most hoped
their research contribution might eventually lead to a cure for
others. A few also commented that by taking part in the
research, other children with similar symptoms might be
diagnosed earlier. Around half also talked about how their
participation might contribute to scientific research more
broadly, and to helping “people in the future”more generally.
Two specifically mentioned wanting to support the NHS or
their particular hospital “any way I can”. Some talked about
this being “an opportunity [to be a] part [of] moving forward
with medicine”. Some explicitly expressed positive views
about pharmaceutical companies having access to their data
for research and developing new treatments. A few described
participating in the project as “not a huge commitment” and
“just a simple thing” that only required “giving a bit of
blood”.
Concerns
Around a quarter of participants said they had had concerns
about data protection and privacy prior to the consent
appointment. One of these participants’ concern about data
protection was unresolved (ongoing concerns about priv-
acy/security changes); he remained concerned because he
had been told that participants would not be informed if any
changes were made regarding data access or protections,
likening this to “your bank changing your terms and con-
ditions and never telling you.”
However, most participants were reassured about their
data security during the consent appointment conversation.
Reassuring factors discussed included that data were “going
to be anonymised” or “won’t be identifiable”, and that there
were legal protections to prevent mishandling of the data,
e.g. “I was reassured [by the consenter] that… if the
researcher does use someone’s data illegally then all their
funding…would be pulled.” No concerns were raised about
the NHS or academic researchers accessing their data, and
only one participant expressed very mild concern about
pharmaceutical companies having access, saying: “I guess
concern is not the right word, but…I might have paused”.
See Table 3 for additional illustrative quotes.
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Attitudes towards secondary findings
Understanding
Most participants recalled unprompted the conversation
about health-related secondary findings, although one could
not recall and another could only vaguely recall the con-
versation. Of those who remembered the secondary findings
conversation, many participants specifically recalled that
additional findings related to cancer could be looked for,
and several specifically recalled heart disease. However, a
few had misunderstandings about results types, i.e. which
secondary findings would be looked for, with some thinking
they would get findings about diabetes, Huntington’s
disease or sickle cell disease. There were also mis-
understandings around the level of control participants had
about the process, e.g. one couple thought they could spe-
cify which conditions they wanted returned, rather than
opting in or out to a set list of conditions. Around one third
of participants specifically mentioned carrier secondary
findings with only a few of these mentioning cystic fibrosis.
Notably, several could not recall being asked and several
could not recall their decision if they had subsequently
signed up to receive secondary findings (the time since the
consent appointment for these participants ranged from 4 to
14 weeks and all but one consented to receive health-related
secondary findings). See Table 4 for illustrative quotes.
Perceived benefits
Almost all participants expressed at least some positive
attitudes towards secondary findings, with around half
expressed only positive attitudes. Many commented that if
they were at increased risk they could be more prepared to
“do something about it, prevent it”, with participants using
terms referring to empowerment, such as “forewarned is
forearmed” when talking about the potential benefits. A
few commented that being at increased risk might influence
lifestyle e.g. changing diet or doing more exercise; others
reflected on their specific role as carer of a child with a rare
Table 3 Understanding and attitudes towards the research uses of the data.
Categories Themes Example quotes
Understanding Contribute to research “they spoke to us about the consent for the pharmaceutical companies and I think
that that’s good because if they’re able to find cures or advance medicine then I’m
happy to do it” P02
Commercial organisations
accessing data
“I’m well aware you know, companies around the world, private companies,
pharmaceutical companies…there’s many companies involved in how research
takes place” P19
University researchers accessing data “you know, if I was against universities looking and doing their research, because
after all they get funding…to do that” P06
Data protection “everything is kept confidential…our names are not matched to the sample” P03
Data storage “I believe the results will be fed into some kind of central database” P06
Perceived benefits Desire to help others with same
condition
“If in ten years’ time if another child is born and the’ve got a similar thing to
Jamie…you know?”P07
May eventually lead to a cure for others “If one day they can find a cure and help other children as well, it will be worth
it” P17
Help others get diagnosed earlier “let’s say another kid comes in with exactly the same display of symptoms and
problems as our son, he might get an answer at the age of one or before” P19
Support NHS “but if we can give something back to the NHS via this new, fledgling project and
help you build, you know, another arm o d the NHS through this whole genome
sequencing…” P14
Importance of pharmaceutical
companies having access to data
“We need to have the pharmaceutical companies to be able to create the
medications to try and help with these conditions.” P16
Concerns Data protection and privacy “So that was my major concern. You don’t want commercial people to be able to
identify you. But I think they relayed all – got rid of all those concerns for us.”
P18
Ongoing concerns about privacy /
security changes
“What happens if in 15 years’ time the rules change in the NHS or the
government changes the rules, would you let us know that effectively the contract
between us has changed slightly?…I remember I specifically asked ‘will you tell
us if things change?’ and she said ‘no’…That’s the point where I thought, hmmm,
you might need to clarify that one for the future…. [It’s like] your bank changing
your terms and conditions and never telling you.” P19
Pharmaceutical companies “I guess concern is not the right word, but…I might have paused”. P20
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disease as a main motivation for consenting to secondary
findings. Several referred to their own family history of
conditions such as cancer and heart disease, and indicated
that they valued the opportunity to know more about
whether those conditions might be passed on. Several
referred to the type of person they were, describing them-
selves as information seekers who “wants to know every-
thing” and another as “fairly laid back”. Some of those
participants were unconcerned about secondary findings
because they perceived a high-risk result to be unlikely e.g.
one participant explicitly said that he thought his risk was
likely to be low.
Concerns
Although many participants expressed only positive atti-
tudes towards receiving secondary findings, just under half
expressed both positive and negative attitudes; in addition,
as noted above, a few couldn’t recall the conversation, or
felt they did not receive enough information to form a view
one way or another. Thus, whilst the decision to opt-in to
secondary findings appeared clear-cut for some participants,
around a third cited both benefits and harms indicating they
were conflicted, ambivalent and found the decision
“tricky.” The main concern about secondary findings was
concern about the potential emotional impact of results, and
feeling worried or anxious about receiving secondary find-
ings. Some people extrapolated from other areas of their life
when thinking about the secondary findings, e.g. one
reflected on the experience when his son had been critically
ill, commenting; “more often than not it helped to know
less…I protected myself in terms of getting information
overload and then worrying about the future.”
A few participants had concerns about implications of
secondary findings for life insurance. A couple of the par-
ticipants spoke about the re-review of the moratorium on
genetics and insurance that is taking place in the UK in
2019, and how this had been an issue they had raised with
the consenter, in particular questioning whether and how it
might affect their current life insurance policy, and expres-
sing concern that the law might change in the future, e.g.
“If I was to take out any new policies there would be
an issue if that law was to change, especially for my
daughters” (P06)
Similarly, another participant was still unclear following
the consent appointment as to whether a change in the law
would affect her life insurance, but commented that, “even
if we had to tell them in 2019…I don’t think I’d withdraw
Table 4 Understanding and attitudes towards secondary findings.
Categories Themes Example quotes
Understanding Cancer “they said they looked at cancer” P03
Heart disease “heart disease for instance” P07
Misunderstandings about results types “I think it was Huntington’s” P16
Misunderstandings about level of control “I think there was a comment box ‘is there anything else you would be interested
in knowing?” P13
Unable to recall being asked “If I was asked that I honestly can’t remember.” P21
Unable to recall decision “I don’t really remember but I would have thought we would have ticked the box
to say that we was happy for any further investigations to be done.” P14
Perceived benefits Preparedness “forewarned is forearmed as far as I’m concerned” P01
Influence lifestyle “if it does come back [as increased risk] try and change your diet or do some
more exercise” P11
Information valuable due to role as
a carer
“Jake is going to need care going forward, so actually my health and wellbeing
is incredibly importance for this situation.” P01
Family history “My wife she has some family history of breast cancer, so I mean if something
comes up on that as part of this study then that is something I suppose we’re
interested in” P13
Information seekers “I’d rather be given everything and know what’s going on and then deal with it
as and when it happens” P05
High-risk result is unlikely “it’s most likely not going to happen” P07
Concerns Feeling worried or anxious “For me personally I think then that’s a whole unknown world where I could
possibly be opening up a world of worries for myself, ‘or what about this or what
about that?’ when in fact those things may never happen.” P13
Concerns about implications for life
insurance
“My only hesitation…whether other companies would be interested in the data…
as in insurance companies” P15
Concerns about future legal changes to
protections
“If I was to take out any new policies there would be an issue if that law was to
change, especially for my daughters” P06
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from the study.” Two other participants had had their initial
concerns about insurance put “to rest” by the consenter.
One of these said he had been reassured about insurance by
the consenter telling them that they “didn’t have to pass
[the information] on if [they] don’t want to”.
Decision support
Overall, participants were very positive about the consent
appointments, describing them as “cohesive,” “informa-
tive,” and “in-depth”. However, a few commented about
the amount of information conveyed; in particular, several
said that having the discussion about the secondary findings
as well as the main findings and research aspects in the
same appointment was “bamboozling” and “a lot to take in
and a lot to process”. One participant wondered whether
“this conversation about additional findings [was] a bit too
close on the back of the other one.”
Feedback about the information sheets was mixed. A few
had not read them, commenting that they did not have time
as their life was too “hectic”. One said this wasn’t an issue
as any questions she had could be addressed during the
appointment. Whilst some had positive comments such as
“informative”, “straight to the point” and “easy to
understand”, others felt there was too much information in
the leaflet, and one mother felt that the focus had been on
her child taking part in research rather than getting him a
diagnosis which had made her “seriously consider not
doing it”. Importantly, this latter participant talked at length
about how important the conversation with the consenter
had been in helping her understand that getting a diagnosis
for her son was actually an important focus for the project,
and that on the basis of this conversation she had subse-
quently decided to take part.
A number of participants said additional sources of
support e.g. online educational tools would have been
valuable alongside the consent appointment. Their sugges-
tions included “animations” or “videos”, as well as static
visual information such as “pictures” and “simple dia-
grams,” rather than only text-heavy paper-based informa-
tion sheets. Online tools were considered particularly useful
because they can be shown “in steps,” because people can
“go back to it at any point,” and because they may be
particularly useful for young children and those with
learning difficulties.
When asked what other questions the information sheet
could address, responses included what additional findings
would be looked for, more information on how genome
sequencing is done, and whether other family members will
receive sequencing results without the knowledge of the
primary carer. As noted above, one participant strongly felt
the information sheet should also have included far greater
emphasis on the diagnostic purpose of the sequencing, as
against primarily the data and research uses. Another par-
ticipant said it should be made clearer that parents would
also be having their genome sequenced. A final suggestion
was that the information sheet should have made it clearer
that they would be asked to make a decision about sec-
ondary findings at the consent appointment.
Discussion
In addition to providing clinical diagnoses for families and
data for discovery research, the 100,000 Genomes Project
provides an important opportunity to learn from patients
themselves about their experiences and outcomes. In this
qualitative interview study, we have identified a broad range
of themes that emerge when participants talked about their
attitudes and understanding, which we have drawn on to
inform the development of new quantitative measures
assessing attitudes and knowledge for larger-scale research
(manuscript in preparation). Furthermore, we identified
several key themes that may have particular relevance to
education, training and policy going forwards.
Attitudes towards data being used for research
Parents taking part in the 100,000 Genomes Project were
understandably motivated by a desire to obtain a diagnosis,
but were also very positive about helping others and con-
tributing to research, findings that support previous research
in this area [20, 21]. This is supportive of the ‘social con-
tract’ as described in the UK Chief Medical Officer’s annual
report Generation Genome [23] and in reports on patient
[24] and public views [25] regarding genomic medicine
commissioned by Genomics England.
However, although participants were very positive about
the research aspects of the project including data sharing, a
novel finding from this work was that some participants still
valued the in-person consent conversation because it gave
them reassurance around data security and protection. This
suggests that written information materials—even if read—
may perhaps not always be able to give adequate reassurance
on this issue. Authors of a recent report on public attitudes to
commercial access to health data found that participants
would have been more trusting if they had known more
about the processes and safeguards in place around data
collection and sharing [26]. Our findings reinforce the
importance of providing patients with the opportunity to ask
questions in addition to providing written information
materials at the time of consent. These findings could be
useful for training of health professionals receiving consent
and discussing the decision with patients. Even if consent
conversations in future clinical contexts are very brief,
training about what type of data security questions patients
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have e.g where is data stored, how it is anonymised, who has
access to it, how and by whom is access granted etc will help
clinicians talk to and reassure patients about how their per-
sonal data will be protected when used for research. This
could include animations explaining how data is protected,
such as those developed by Genomics England for the
100,000 Genomes Project, could also be adapted for use in
the new NHS Genomic Medicine Service [27].
Issues around secondary findings
Participants raised several issues around secondary find-
ings. This included misunderstandings about what types of
conditions were included on the list of secondary findings
(participants were informed they would learn about clini-
cally ‘actionable’ findings, which was the term used in the
consent form, however, we have observed that consenters
did frequently cite ‘cancer’ and ‘heart disease’ during
consent appointments [28]), as well as whether they had
personally opted to receive to secondary findings. These
findings are consistent with a previous UK study in which
many participants couldn’t recall their decision about
secondary findings at the time of consent [15]. Where our
findings add to the existing research is that we also found
that several parents felt it was overwhelming to have the
conversation about secondary findings at the same time as
the conversation about the main findings. Whilst this is a
concern that has been raised elsewhere in the literature
[29], we are unaware of other studies where this concern
was realised in clinical practice. In our previous study in
which 21 consent conversations between consenters and
potential participants in the 100,000 Genomes Project
were audio-recorded and analysed, we found that in most
cases consenters spent relatively little time (usually
<5 min) discussing secondary findings with potential
participants [28]. Taking more time to discuss secondary
findings may alleviate the risk of patients being over-
whelmed by information. However, a tension exists
between the need to provide comprehensive pre-test
counselling, including allocating time for patients to con-
sider their decision, and at the same time the practical
reality of time-constrained appointments.
Together, our findings have implications for policy and
practice as genome sequencing starts to be integrated into
clinical practice in the UK and elsewhere globally. If the
option of receiving secondary findings is offered at the same
time as consent for main findings, greater time for the
secondary findings discussion is needed. This may incur
additional costs and resources and online decision support
tools that complement the in-person conversation may
therefore be particularly useful in this context. A number
of web-based decision aids have been developed to
support patients making genomic testing decisions, reduce
decisional conflict and enhance the patient-provider
communication in recent years [30, 31]. The Genomics
ADvISER was specifically developed to support patients’
decisions about learning secondary findings [30] and is
current being evaluated through a mixed methods rando-
mised controlled trial [32].
However, participants’ main concern about secondary
findings was the potential psychological harm that the
results might have on them. This concern has been iden-
tified in previous qualitative research [12, 15]. In our
previous observational study [28], most of the consent
conversation was dedicated to providing patients with
biomedical information and information about the project,
e.g. data security, rather than discussing potential
psychosocial impact. A US group recently recommended
that ‘complex’ findings with potential psychological and
serious health implications such as BRCA1/2 should
involve a dedicated conversation with an appropriately
trained healthcare professional and with appropriate sup-
porting information materials [33]. While this may not be
realistic going forwards, if secondary findings (including
BRCA1/2) are to be returned in future clinical settings,
empirical evidence is urgently needed to inform best
practice and policy decisions about consent and pre-test
counselling, education and the need for follow up
appointments. This includes evidence on both the patient-
provider communication around the time of consent, and
the psychological impact of secondary findings once they
have been returned.
Concerns about implications of secondary findings for
life insurance were also raised and not easily addressed
because of possible future changes to legal and other pro-
tections. The finding that people considering genetic or
genomic testing are concerned about insurance is not a new
observation [15, 34]. However, our study adds insight on
people’s views regarding protections in this area. Patients
and research participants are often informed that they are
protected in terms of insurance, e.g. GINA in the US [35],
and the Code on genetic testing and insurance in the UK
[36]. However, our findings indicate that at least some
people are not reassured by these current protections,
because they recognise these might be removed or changed
in the future. Training for clinicians offering genomic
testing to patients therefore needs to take this into account.
Clinicians need to be prepared to answer patients’ questions
about the implications of genomic testing for life or health
insurance; they need to be up-to-date on current policy on
protections and foreseeable changes to these where possi-
ble, or at least know where (e.g. relevant websites) to direct
patients/families to find out more.
Limitations of our study include that it was a small
qualitative study and so may not be generalisable to the
population from which the sample was drawn. In addition,
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all the interviews were done over the telephone, which may
have contributed to the brevity of some of the interviews.
Unfortunately, due to repeated rearrangement of interviews
in a number of cases, there was a large time-lag between the
consent appointment and the interview taking place (in one
case this was 17 weeks). This may have impacted recall of
information given about the study. Interviews were con-
ducted before the parents had received any main or sec-
ondary findings and their views may change after receiving
these findings. Thus evaluation of attitudes after return of
results is an important line of investigation for future
research. It is also important to bear in mind that going
forward, genome sequencing will be used as a first-line test
for many rare disease patients, and unlike the participants in
the 100,000 Genomes Project, these patients may not have
had any previous genetic testing. Their support and infor-
mation needs may differ to the participants in the 100,000
Genomes Project; for example they may less familiar with
genetic and genomic concepts or the limitations and
uncertainties associated with this type of testing. However,
our findings provide novel insights into UK parents’ current
attitudes, concerns, understanding and information needs,
provides empirical evidence for policymakers, and are of
value to researchers developing interventions for patients
undergoing genomic sequencing.
In conclusion, our study findings suggest that current
consent procedures may effectively support parents in
decision-making about genome sequencing for diagnosis
and research, but also that more research is warranted into
development and evaluation of online decision support
tools, and whether and how secondary findings from gen-
ome sequencing should be offered clinically. Additional
qualitative as well as large-scale research on outcomes after
personal results have been returned to parents and patients
will also be vital to inform the development of policy and
practice.
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